Amicus Therapeutics (FOLD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 09-2025 | 06-2025 | 03-2025 | 12-2024 | |
| Sales | 185,212 | 169,061 | 154,688 | 125,249 | 149,706 |
| Cost of Goods | 26,547 | 19,467 | 15,217 | 11,698 | 14,836 |
| Gross Profit | 158,665 | 149,594 | 139,471 | 113,551 | 134,870 |
| Operating Expenses | 143,266 | 115,792 | 149,162 | 122,201 | 119,735 |
| Operating Income | 15,946 | 34,269 | -9,474 | -7,952 | 15,971 |
| Interest Expense | 11,428 | 11,711 | 11,565 | 11,455 | 11,958 |
| Other Income | -1,375 | 11,716 | 1,858 | 1,362 | 3,921 |
| Pre-tax Income | 3,143 | 34,274 | -19,181 | -18,045 | 7,934 |
| Income Tax | 1,453 | 16,968 | 5,239 | 3,641 | -6,805 |
| Net Income Continuous | 1,690 | 17,306 | -24,420 | -21,686 | 14,739 |
| Net Income | $1,690 | $17,306 | $-24,420 | $-21,686 | $14,739 |
| EPS Basic Total Ops | 0.00 | 0.06 | -0.08 | -0.07 | 0.05 |
| EPS Basic Continuous Ops | 0.01 | 0.06 | -0.08 | -0.07 | 0.05 |
| EPS Diluted Total Ops | 0.00 | 0.06 | -0.08 | -0.07 | 0.05 |
| EPS Diluted Continuous Ops | 0.01 | 0.06 | -0.08 | -0.07 | 0.05 |
| EPS Diluted Before Non-Recurring Items | 0.02 | 0.11 | -0.05 | -0.05 | 0.03 |
| EBITDA(a) | $18,519 | $36,801 | $-6,992 | $-5,509 | $18,609 |